Association of high-molecular-weight to total adiponectin ratio with pulse wave velocity in hemodialysis patients

Nephron - Clinical Practice

Volumn 109, Issue 1, 2008, Pages

  Kato, Akihiko ^a   Odamaki, Mari ^b   Ishida, Junko ^b   Hishida, Akira ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HAMAMATSU UNIVERSITY   (Japan)

Author keywords

Abdominal fat mass; Arterial stiffness; Hemodialysis; High molecular weight adiponectin

Indexed keywords

ADIPONECTIN; INTERLEUKIN 6;

ABDOMINAL FAT; ADULT; AGED; ARTERIAL STIFFNESS; ARTERIOSCLEROSIS; ARTERY COMPLIANCE; ARTICLE; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; PRIORITY JOURNAL; PULSE WAVE;

ADIPONECTIN; AGED; ARTERIOSCLEROSIS; BLOOD FLOW VELOCITY; BLOOD PRESSURE; FEMALE; HUMANS; MALE; RENAL DIALYSIS;

EID: 46349102404     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000134014     Document Type: Article

References (31)

1. Kadowaki T, Yamauchi T: Adiponectin and adiponectin receptors. Endocr Rev 2005;26:439-451.
2. Kobayashi H, Ouchi N, Kihara S, et al: Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 2004;94:e27-e31.
3. Bodles AM, Banga A, Rasouli N, et al: Pioglitazone increases secretion of high-molecular weight adiponectin from adipocytes. Am J Physiol 2006;292:E1100-E1105.
4. Nakashima R, Kamei N, Yamane K, et al: Decreased total and high molecular weight adiponectin are independent risk factors for the development of type 2 diabetes in Japanese-Americans. J Clin Endocrinol Metab 2006;91:3873-3877.
5. Hara K, Horikoshi M, Yamauchi T, et al: Measurement of the high molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 2006;29:1357-1362.
6. Katsuki A, Suematsu M, Gabazza EC, et al: Decreased high molecular weight adiponectin-to-total adiponectin ratio in sera is associated with insulin resistance in Japanese metabolically obese, normal-weight men with normal glucose tolerance. Diabetes Care 2006;29:2327-2328.
7. Komaba H, Igaki N, Goto S, et al: Increased serum high-molecular weight complex of adiponectin in type 2 diabetic patients with impaired renal function. Am J Nephrol 2006;26:476-482.
8. Shen YY, Charlesworth JA, Kelly JJ, et al: Up-regulation of adiponectin, its isoforms and receptors in end-stage kidney disease. Nephrol Dial Transplant 2007;22:171-178.
9. Shen YY, Charlesworth JA, Kelly JJ, Peake PW: The effect of renal transplantation on adiponectin and its isoforms and receptors. Metabolism 2007;56:1201-1208.
10. Okura T, Watanabe S, Kurata M, et al: Relationship between cardio-ankle vascular index (CAVI) and carotid atherosclerosis in patients with essential hypertension. Hypertens Res 2007;30:335-340.
11. Odamaki M, Furuya R, Kinumura Y, et al: Association between plasma adiponectin concentration and visceral fat accumulation in hemodialysis patients. Nephron 2006;102:c8-c13.
12. Odamaki M, Shibata T, Takita T, Kumagai H: Serum fetuin-A and aortic calcification in hemodialysis patients. Kidney Int 2005;68:2916.
13. Yambe T, Yoshizawa M, Saijo Y, et al: Brachio-ankle pulse wave velocity and cardioankle vascular index (CAVI). Biomed Pharmacother 2004;58(suppl 1):S95-S98.
14. Shirai K, Utino J, Otsuka K, Takata M: A novel blood pressure-independent arterial wall stiffness parameter; cardio-ankle vascular index (CAVI). J Atheroscler Thromb 2006;13:101-107.
15. Araki T, Emoto M, Yokoyama H, et al: The association of plasma adiponectin level with carotid arterial stiffness. Metabolism 2006;55:587-592.
16. Mahmud A, Feely J: Adiponectin and arterial stiffness. Am J Hypertens 2005;18:1543-1548.
17. Aso Y, Yamamoto R, Wakabayashi S, et al: Comparison of serum high molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using an oval enzyme-linked immunosorbent assay to detect HMW adiponectin. Diabetes 2006;55:1954-1960.
18. Inoue T, Kotooka N, Morooka T, et al: High molecular adiponectin as a predictor of long-term clinical outcome in patients with coronary artery disease. Am J Cardiol 2007;100:569-574.
19. Zoccali C, Mallamaci F, Tripepi G, et al: Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002;13:134-141.
20. Becker B, Kronenberg F, Kielstein JT, et al: Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: The Mild and Moderate Kidney Disease Study. J Am Soc Nephrol 2005;16:1091-1098.
21. Iwashima Y, Horio T, Kumada M, et al: Adiponectin and renal function, and implications as a risk of cardiovascular disease. Am J Cardiol 2006;98:1603-1608.
22. Diez JJ, Iglesias P, Fernandez-Reyes MJ, et al: Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with endstage renal disease. Clin Endocrinol 2005;62:242-249.
23. Ignacy W, Chudek J, Adamczak M, et al: Reciprocal association of plasma adiponectin and serum C-reactive protein concentration in haemodialysis patients with end-stage kidney disease - a follow-up study. Nephron Clin Pract 2005;101:c18-c24.
24. Kistrop C, Faber J, Galatius S, et al: Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005;112:1756-1762.
25. Schalkwijk CG, Chaturvedi N, Schram MT, et al: Adiponectin is inversely associated with renal function in type 1 diabetic patients. J Clin Endocrinol Metab 2006;91:129-135.
26. Wannamethee SG, Whincup PH, Lennon L, Sattar N: Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch Intern Med 2007;167:1510-1517.
27. Kollerits B, Fliser D, Heid IM, et al: Gender-specific association of adiponectin as a predictor of progression of chronic kidney disease: The Mild to Moderate Kidney Disease Study. Kidney Int 2007;71:1279-1286.
28. Ohashi N, Kato A, Misaki T, et al: Association of serum adiponectin levels with allcause mortality in hemodialysis patients. Intern Med 2008;47:485-491.
29. McEntegart MB, Awede B, Petrie MC, et al: Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur Heart J 2007;28:829-835.
30. Malyszko J, Malyszko JS, Brzosko S, et al: Adiponectin is related to CD146, a novel marker of endothelial cell activation/injury in chronic renal failure and peritoneally dialyzed patients. J Clin Endocrinol Metab 2004;89:4620-4627.
31. Fésüs G, Dubrovska G, Gorzelniak K, et al: Adiponectin is a novel humoral vasodilator. Cardiovasc Res 2007;75:719-727.